Ark Therapeutics signs a letter of intent with EMD Millipore
07:13 EDT 17 Aug 2012 | CentreWatch
Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral..
Original Article: Ark Therapeutics signs a letter of intent with EMD Millipore
More From BioPortfolio on "Ark Therapeutics signs a letter of intent with EMD Millipore"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
